

Johannes F E Mann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3906023/publications.pdf>

Version: 2024-02-01

78
papers

14,473
citations

76326

40
h-index

62596

80
g-index

82
all docs

82
docs citations

82
times ranked

14297
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter regarding “diagnosis and treatment of arterial hypertension 2021” Kidney International, 2022, 101, 828-830.	5.2	1
2	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 2022, 145, 575-585.	1.6	88
3	Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial. BMJ Open, 2022, 12, e051907.	1.9	4
4	Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers. Frontiers in Pharmacology, 2022, 13, 786767.	3.5	2
5	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia, 2022, 65, 1085-1097.	6.3	28
6	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care, 2021, 44, 1020-1026.	8.6	30
7	Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. Kidney International, 2021, 99, 314-318.	5.2	14
8	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. Journal of Hypertension, 2021, 39, 766-774.	0.5	9
9	Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 2021, 99, 559-569.	5.2	169
10	Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2058-2066.	4.4	33
11	Commentary on the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD. Current Cardiology Reports, 2021, 23, 132.	2.9	5
12	Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 1270-1281.	3.9	41
13	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	5.2	65
14	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1 “7 randomised controlled trials. Lancet Diabetes and Endocrinology, 2020, 8, 880-893.	11.4	86
15	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	8.6	92
16	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. Diabetes, Obesity and Metabolism, 2020, 22, 2077-2088.	4.4	10
17	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 465-473.	4.5	32
18	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care, 2020, 43, 1803-1812.	8.6	44

#	ARTICLE	IF	CITATIONS
19	SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	4
20	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1027-1036.	5.2	60
21	Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. BMC Nephrology, 2019, 20, 81.	1.8	6
22	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. European Heart Journal, 2019, 40, 2032-2043.	2.2	47
23	Blood HER2 and Uromodulin as Causal Mediators of CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 1326-1335.	6.1	21
24	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation, 2018, 138, 2908-2918.	1.6	88
25	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140) mmHg in overweight and obese patients. European Heart Journal, 2018, 39, 3105-3114.	2.2	92
26	Long-term treatment with biosimilar epoetin- α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study. Clinical Nephrology, 2018, 89, 1-9.	0.7	7
27	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet, The, 2017, 389, 2226-2237.	13.7	263
28	Liraglutide and Renal Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 839-848.	27.0	903
29	Liraglutide and Renal Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 2195-2198.	27.0	31
30	One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrology Dialysis Transplantation, 2017, 32, 1918-1926.	0.7	21
31	Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet, The, 2016, 388, 465-475.	13.7	381
32	Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study. American Journal of Kidney Diseases, 2016, 68, 29-40.	1.9	46
33	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 311-322.	27.0	5,070
34	Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Kidney International, 2016, 89, 1380-1387.	5.2	27
35	Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study. , 2016, 26, 288-298.		68
36	Dual renin-angiotensin system blockade and outcome benefits in hypertension. Current Opinion in Cardiology, 2015, 30, 373-377.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?. Nephrology Dialysis Transplantation, 2015, 30, iv1-iv5.	0.7	9
38	Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. Nephrology Dialysis Transplantation, 2015, 30, iv76-iv85.	0.7	31
39	Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. Nephrology Dialysis Transplantation, 2015, 30, iv26-iv34.	0.7	41
40	Risk Prediction for Early CKD in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1371-1379.	4.5	97
41	Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 1037-1046.	0.7	109
42	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney International, 2015, 87, 784-791.	5.2	86
43	Sodium Intake and Renal Outcomes: A Systematic Review. American Journal of Hypertension, 2014, 27, 1277-1284.	2.0	66
44	A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. Internal and Emergency Medicine, 2013, 8, 389-399.	2.0	9
45	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal, 2013, 166, 823-830.e5.	2.7	182
46	Dual RAS blockade—unresolved controversy?. Nature Reviews Nephrology, 2013, 9, 640-640.	9.6	1
47	Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes. Journal of Hypertension, 2013, 31, 414-421.	0.5	72
48	Estimated Glomerular Filtration Rate and Albuminuria as Predictors of Outcomes in Patients With High Cardiovascular Risk. Annals of Internal Medicine, 2011, 154, 310.	3.9	74
49	Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease. Journal of the American Society of Nephrology: JASN, 2011, 22, 1353-1364.	6.1	234
50	What's new in hypertension 2010?. Nephrology Dialysis Transplantation, 2011, 26, 50-55.	0.7	4
51	Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk. Circulation, 2011, 123, 1098-1107.	1.6	135
52	Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clinical Nephrology, 2011, 76, 9-15.	0.7	16
53	Avosentan for Overt Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2010, 21, 527-535.	6.1	428
54	What's new in hypertension 2009?. Nephrology Dialysis Transplantation, 2010, 25, 37-41.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Effect of Telmisartan on Renal Outcomes. Annals of Internal Medicine, 2009, 151, 1.	3.9	163
56	The COOPERATE trial: a letter of concern. Lancet, The, 2008, 371, 1575-1576.	13.7	89
57	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) Tj ETQq1 1 0.784314 rgBT /Overlook	13.7	1,442
58	What's new in hypertension 2008?. Nephrology Dialysis Transplantation, 2008, 24, 38-42.	0.7	5
59	Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Annals of Internal Medicine, 2008, 148, 30.	3.9	626
60	Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrology Dialysis Transplantation, 2007, 23, 645-653.	0.7	82
61	What's new in hypertension 2007?. Nephrology Dialysis Transplantation, 2007, 23, 466-470.	0.7	1
62	Chronic Kidney Disease. Circulation, 2007, 116, 85-97.	1.6	1,278
63	Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clinical Nephrology, 2007, 67, 140-148.	0.7	27
64	Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. American Journal of Kidney Diseases, 2006, 48, 889-896.	1.9	25
65	Clinic versus home blood-pressure measurements as a predictor of outcomes in chronic kidney disease. Nature Clinical Practice Nephrology, 2006, 2, 474-475.	2.0	1
66	What's new in hypertension?. Nephrology Dialysis Transplantation, 2006, 22, 47-52.	0.7	1
67	Optimal Treatment of Renal Anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. Nephrology Dialysis Transplantation, 2005, 20, iii25-iii32.	0.7	25
68	Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. Presse Medicale, 2005, 34, 1303-1308.	1.9	18
69	How Does Minor Renal Dysfunction Influence Cardiovascular Risk and the Management of Cardiovascular Disease?. Journal of the American Society of Nephrology: JASN, 2004, 15, 517-523.	6.1	55
70	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney International, 2004, 65, 1375-1380.	5.2	102
71	Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney International, 2004, 66, S59-S62.	5.2	70
72	Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases, 2003, 42, 936-942.	1.9	75

#	ARTICLE	IF	CITATIONS
73	Cardiovascular risk in patients with mild renal insufficiency. <i>Kidney International</i> , 2003, 63, S192-S196.	5.2	61
74	Development of Renal Disease in People at High Cardiovascular Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 641-647.	6.1	130
75	Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes: Results of the HOPE Study and MICRO-HOPE Substudy. <i>Diabetes Care</i> , 2002, 25, 1919-1927.	8.6	349
76	Cardiovascular Risk in Patients with Early Renal Insufficiency. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 157-162.	2.2	29
77	ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1100-1108.	6.1	110
78	Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 105-115.	6.1	206